Here’s whether Royalty Pharma plc Class A Ordinary Shares (RPRX) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.69% over 10 days); RSI 59 — healthy momentum range; strong 1-year return of +60.8%; 3-month momentum positive (+19.1%). Currently 1.5% off its 52-week high. Score: +7/7.
RPRX is in a confirmed uptrend, trading above both its 50-day ($55.49) and 200-day ($45.86) moving averages. An RSI of 59.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +60.8% compares to +16.5% for SPY (beat the market by 44.3%).
$10,000 invested 1 year ago→ $16,078 today
vs. S&P 500 (SPY) — same period beat market by 44.3%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($45.86)
✓Above 50-day MA ($55.49)
✓RSI(14) neutral zone (30–70) — currently 59.4
✓Positive return (+60.8%)
✓Within 10% of period high (−1.5%)
Period Range $58.83
$34.08$59.72
RSI (14) 59.4
0 · OversoldOverbought · 100
Key Metrics
Price$58.83
Period Return+60.8%
Period High$59.72
Period Low$34.08
Drawdown−1.5%
MA-50$55.49
MA-200$45.86
RSI (14)59.4
Avg Volume (30d)3.3M
vs. SPYbeat by 44.3%
Return Rank#161 of 999
Trend Signals
Price is above the 200-day moving average ($45.86)